Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Фаза 3
Завершено
NCT04737187
| Заболевание | Refractory Metastatic Colorectal Cancer |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Taiho Oncology, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 492 участн. |
|---|
| Вмешательство | Trifluridine/Tipiracil, Bevacizumab |
|---|
| Дата начала | 25.11.2020 |
|---|
| Дата завершения | 19.07.2022 |
|---|
| Публикация результатов | 26.12.2023 |
|---|
Кратко
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
Overall Survival (OS)
From date of randomization to the death due to any cause or cut-off date, whichever comes first (maximum duration: up to 20 months) · months
| Trifluridine/Tipiracil + Bevacizumab | 10.78 months |
|---|
| Trifluridine/Tipiracil | 7.46 months |
|---|
| p-value | < 0.001 |
|---|
| Hazard Ratio (HR) | 0.61 (95% CI 0.49–0.77) |
|---|
Survival Probability at 6 Months
From date of randomization until 6 months post treatment · probability of participants
| Trifluridine/Tipiracil + Bevacizumab | 0.77 probability of participants |
|---|
| Trifluridine/Tipiracil | 0.61 probability of participants |
|---|
Survival Probability at 12 Months
From date of randomization until 12 months post treatment · probability of participants
| Trifluridine/Tipiracil + Bevacizumab | 0.43 probability of participants |
|---|
| Trifluridine/Tipiracil | 0.30 probability of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.